Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;39(4):1043-8.
doi: 10.1007/s11255-007-9179-9. Epub 2007 Mar 6.

The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients

Affiliations

The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients

Müjgan Cengiz et al. Int Urol Nephrol. 2007.

Abstract

Glutathione S transferases (GSTT1, GSTM1, GSTP1) are enzymes that activate the detoxification of endogenous and exogenous agents. The genetic polymorphism in these genes may change the response of individuals to environmental toxicants. The genetic polymorphisms of GSTT1, GSTM1, GSTP1 have been studied extensively in the determination of individual cancer risks. Some studies showed a strong relationship between polymorphism of GSTs and superoxidedismutase enzymes. Using the polymerase chain reaction (PCR) the prevalence of genetic polymorphisms of GSTT1, GSTM1 and MnSOD (Manganese Superoxide Dismurase) was investigated in 104 cases and controls to seek any association with the risk of bladder cancer. The frequency of GSTT1 +/+ polymorphism was 65% (33/51) in the cases and 79% (42/53) in the controls. The frequency of the GSTM1 +/+ polymorphism was 33% (17/51) in the cases and 58% (31/53) in the controls. The frequency of the GSTM1 null genotype was 42% (22/53) in the controls and 68% (34/51) in the patients. The frequency of the SOD AA genotype was 36% (17/51) in the cases and 33% (19/53) in the controls. There was no association between the GSTT1 and SOD polymorphism and bladder cancer incidence. The incidence of the GSTM1 null genotype was increased in bladder cancer patients compared to controls (OR = 1.755, 95% CI = 1.119-2.751).

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur Urol. 2000 Jun;37(6):660-4 - PubMed
    1. Int J Epidemiol. 1999 Oct;28(5):829-35 - PubMed
    1. Eur Urol. 2005 Aug;48(2):339-44 - PubMed
    1. Carcinogenesis. 1993 Sep;14(9):1821-4 - PubMed
    1. Biochem J. 1994 May 15;300 ( Pt 1):271-6 - PubMed

LinkOut - more resources